FDA to quickly review Novartis’ capmatinib in rare lung cancerThe FDA has agreed to fast-track its regulatory review of Novartis’ capmatinib in a hard-to-treat form of lung Share XFDA to quickly review Novartis’ capmatinib in rare lung cancerhttps://pharmaphorum.com/news/fda-to-quickly-review-novartis-capmatinib-in-rare-lung-cancer/
